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Bone marrow (BM) neoangiogenesis plays an important role in acute myelogenous leukaemia (AML), and depends on the interplay of
members of the vascular endothelial growth factor (VEGF) and angiopoietin (Ang) families. We determined the marrow levels of
seven molecules associated with angiogenesis in 52 AML patients before chemotherapy and 20 healthy controls: VEGF-A, VEGF/
PlGF, VEGF-C, VEGF-D, Ang-1, Ang-2, and Tie-2. All the molecules were quantified using enzyme-linked immunosorbent assay
(ELISA). Comparing to normal controls, the marrow levels of VEGF/PlGF, Ang-2, and Tie-2 were significantly higher, and those of
VEGF-C and Ang-1 were significantly lower in the AML patients (Po0.001). A total of 31 patients were further subjected to survival
analysis. Patients with lower Tie-2 (o26ngml
 1) and Ang-2 levels (o4500pgml
 1) displayed a survival advantage (P¼0.037 and
0.042, respectively), same as patients with higher VEGF/PlGF (X1pgml
 1) and VEGF-D levels (X350pgml
 1)( P¼0.020 and 0.016,
respectively). An angio-index ((Ang-2 Tie-2)/(VEGF/PlGF VEGF-D)) was established and multivariate Cox regression analysis
revealed that patients with higher angio-index values (X50) displayed poor prognosis (hazard ratio 5.91, 95% confidence interval
1.99–17.56; P¼0.001). The angio-index is closely associated with the clinical outcome of AML patients and may be valuable in
disease prognosis.
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Vascular endothelial growth factor (VEGF) and angiopoietin (Ang)
are the two families involved in the regulation of vascular
angiogenesis. The VEGF family comprises six members: VEGF-A,
-B, -C, -D, -E, and placental growth factor (PlGF). They share three
receptors, ie VEGFR-1, -2, and -3 (Korpelainen and Alitalo, 1998;
Podar and Anderson, 2005). The Ang family includes four
members: Ang-1, -2, -3, and -4. However, they share only a single
receptor, ie Tie-2 (Ward and Dumont, 2002).
Both in vitro and in vivo investigations have revealed that
VEGF-A was present in a high concentration in the bone marrow
(BM) cells of AML patients and the vast majority of myeloblasts
(490%) could synthesise and secrete VEGF-A (Ghannadan et al,
2003). Compared to the levels in the control, increased plasma
levels of VEGF-A obtained from peripheral blood (PB) were
observed in AML patients (Aguayo et al, 2000, 2002). Elevated
VEGF-C expression was reported in patients with prostatic
carcinoma and oesophageal squamous cell carcinoma (Tsurusaki
et al, 1999; Kitadai et al, 2001) but is controversial with regard to
AML patients (Fielder et al, 1997; Dias et al, 2002; Loges et al,
2005). In contrast, decreased VEGF-D expression levels were
reported in patients with lung adenocarcinoma and colorectal
carcinoma (Niki et al, 2000; Onogawa et al, 2004). However, no
previous reports addressed plasma VEGF-C and -D levels.
Both Ang-1 and -2 can only bind to the Tie-2 receptor, but they
have opposite effects on Tie-2 activation. Tie-2 is a receptor
tyrosine kinase that is expressed on endothelial cells (ECs) and
haematopoietic stem cells (HSCs). Ang-1 functions as a stabilising
signal for mature vasculature, and Ang-2 can be regarded as a
regulator of vessel plasticity (Jones, 2003). In the BM niche, Ang-1/
Tie-2 signalling occurs during interaction between Tie-2-expres-
sing HSCs and Ang-1-expressing osteoblasts (Arai et al, 2004; Arai
et al, 2005); this maintains the HSCs in the quiescence and anti-
apoptotic state. Data from recent studies indicate that Ang-2
expression represents an independent prognostic factor in AML
(Loges et al, 2005). However, the limitation of these studies was
that plasma samples of the study patients were not available; thus,
the investigation was restricted to the analysis of the mRNA
expression of angiogenic factors. Therefore, precise data on the
protein concentrations are essential.
Neoangiogenesis depends on the interplay of different members
of the VEGF and Ang family, and many of these factors that are
present in significant amounts in the marrow environment may
function in a synchronised fashion in addition to any local
autocrine or paracrine effects they may have; therefore, compre-
hensive analyses on marrow levels of these factors in AML patients
and the clinical implications of these levels are important and
remain to be explored.
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sMATERIALS AND METHODS
Study subjects
Prior to chemotherapy, marrow samples were obtained from 52
newly diagnosed AML patients at National Taiwan University
Hospital (Taipei, Taiwan) from 1998 to 1999. This study was
approved by the Institutional Review Board of the hospital (serial
no 9461712129), and written informed consent was obtained from
all patients. The study included 33 males and 19 females. The ages
of the patients ranged from 2 to 90 years, with a median age of 45
years. According to the French–American–British (FAB) classifi-
cation, two patients were classified as M0; 15, M1; 17, M2; 7, M3; 8,
M4; 2, M5; and 1, unclassified. Of these, 14 patients did not
undergo chemotherapy or were only treated with low-dose
cytosine arabinoside due to old age and/or poor performance
status; all the other patients with non-M3 AML subtypes under-
went conventional induction chemotherapy with one of the
anthracyclines (doxorubicin or idarubicin) for 3 days and cytosine
arabinoside for 7 days. The patients with acute promyelocytic
leukaemia (subtype M3) received all-trans retinoic acid with or
without concurrent induction chemotherapy. After the patients
achieved complete remission (CR), they underwent consolidation
chemotherapy with a conventional dose of cytosine arabinoside
and one anthracycline or with high-dose cytosine arabinoside. On
the basis of tri-lineage cell regeneration with o5% blasts in the
BM, normalisation of the PB cell count and the absence of
leukaemia infiltration in the tissue, the patients were considered to
have achieved CR. In addition, 20 healthy marrow donors were
included as healthy controls in this study; of these, 10 were males
and 7 females. The age of the control patients ranged from 11 to 56
years, with a median age of 32 years. After collection, the marrow
samples were immediately centrifuged, and the plasma was
separated and stored at  201C until investigation.
Enzyme-linked immunosorbent assay
One-step sandwich enzyme immunoassay was performed to
measure the VEGF-A, VEGF/PlGF, VEGF-C, VEGF-D, Ang-1,
Ang-2, and Tie-2 concentrations by using commercially available
kits (R&D systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions.
The results represent the mean values of the duplicate
determinations and were calculated using the SoftMax Pro 4.8
software (Molecular Devices Corporation, Sunnyvale, CA, USA).
Statistical methods
Student’s t-test and analysis of variance (ANOVA) were used to
analyse the angiogenesis factors in the age, sex, FAB subtype, and
karyotype subgroups of the AML patients. Spearman’s test was
used to analyse the correlation between the factors. The receiver
operating characteristic (ROC) curve was constructed, and the area
under the ROC curve (AUROC) was calculated for each factor to
differentiate the patients from the controls. The paired t-test was
used for patients who achieved CR to determine the difference
between the concentrations of the various factors at presentation
and CR. Survival status was investigated by using the Kaplan–
Meier survival curve and log-rank test. Univariate and multivariate
Cox regression analyses were also used to estimate prognosis. All
the statistical analyses were performed by using the MedCalc
software (http://www.medcalc.be/) and the SPSS 12.0 statistical
software (SPSS Inc., Chicago, IL, USA).
RESULTS
Lack of correlation between plasma levels of seven
angiogenesis-related factors in marrow and the egress of
leukaemic cells from the BM to PB
The seven angiogenesis-related factors (VEGF-A, VEGF/PlGF,
VEGF-C, VEGF-D, Ang-1, Ang-2, and Tie-2) in 52 AML patients
at presentation were investigated, and no significant differences
were observed in the age and FAB subtypes (Table 1). However,
Tie-2 level was higher in males than that in females (P¼0.024),
Table 1 Characteristics of the study groups
No.
VEGF
(pgml
 1)
VEGF/PlGF
(pgml
 1)
VEGF-C
(pgml
 1)
VEGF-D
(pgml
 1)
Ang-1
(pgml
 1)
Ang-2
(pgml
 1)
Tie-2
(ngml
 1)
Age
o45 25 47.85±43.85 8.52±10.63 378.89±258.09 614.55±381.32 1344.02±939.19 3977.02±2741.20 23.89±8.15
X45 27 31.49±19.37 19.02±37.01 389.53±247.86 879.69±582.55 1509.71±939.30 2936.34±2742.42 21.81±7.60
P-value 0.096 0.168 0.880 0.057 0.528 0.178 0.346
Sex
Male 33 41.40±36.56 15.45±31.14 391.74±251.72 844.10±560.19 1279.31±800.31 3192.22±2513.06 24.52±8.36
Female 19 35.81±30.03 11.41±21.78 371.70±254.39 592.64±366.79 1691.86±1103.48 3861.23±3183.72 19.83±6.03
P-value 0.554 0.587 0.785 0.057 0.164 0.438 0.024
a
FAB subtype
M0 2 44.13±35.22 9.09±9.20 282.84±21.65 829.40±517.51 1725.07±915.97 1213.66±585.51 24.32±0.74
M1 15 35.48±44.46 3.39±3.68 348.72±186.96 764.07±703.42 1480.47±659.10 3283.47±2327.49 23.40±5.71
M2 17 37.55±25.65 26.76±40.63 417.03±338.62 726.52±462.79 1735.12±1350.26 3362.76±3219.54 20.18±8.67
M3 7 71.88±37.89 7.80±10.92 413.84±131.58 687.09±279.06 783.75±269.15 3951.64±3160.14 24.29±3.90
M4 8 26.14±14.28 17.32±31.84 459.35±263.12 667.53±321.93 1464.84±440.60 4131.93±3134.01 24.75±8.85
M5 2 20.11±1.35 4.35±5.22 89.07±10.65 820.14±272.82 545.18±137.94 3460.07±1308.26 28.80±24.15
P-value 0.133 0.275 0.505 0.996 0.211 0.855 0.583
Cytogenetic subtype
Favourable 7 55.14±45.01 8.44±10.51 369.97±159.36 702.40±271.53 988.34±848.59 2952.35±2516.61 21.87±5.73
Intermediate 29 37.08±37.03 18.48±35.32 426.92±301.19 726.98±445.84 1735.36±1029.81 3588.60±3129.72 24.55±9.18
Unfavourable 16 36.58±21.30 8.22±13.77 313.69±157.26 819.76±688.43 1069.93±535.84 3373.17±2240.56 20.07±5.06
P-value 0.429 0.434 0.351 0.817 0.026
a 0.861 0.179
aDenotes significant difference. Abbreviations: Ang¼angiopoietin; ANOVA¼analysis of variance; FAB¼French–American–British; PlGF¼placental growth factor;
VEGF¼vascular endothelial growth factor. Age and sex were analysed using Student’s t test, and FAB subtypes and cytogenetic subtype were analysed using ANOVA.
Favourable cytogenetic subtype: t(15; 17), t(8; 21), and inv(16); unfavourable:  5,  7, +8, and complex; and intermediate: normal cytogenetic subtype and others.
Marrow angiogenesis factors in AML
C-Y Lee et al
878
British Journal of Cancer (2007) 97(7), 877–882 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sand the Ang-1 level was significantly different among the
karyotype subgroups (P¼0.026).
To clarify whether these seven molecules present in the marrow
microenvironment could determine the extent of egress of
immature haematopoietic cells from the BM to PB, we correlated
the absolute number of immature cells in the PB with the marrow
levels of these molecules at disease presentation. We found that the
marrow levels did not correlate with the egress of leukaemic cells
from the BM to PB (VEGF-A, r¼ 0.050; VEGF/PlGF, r¼0.229;
VEGF-C, r¼0.229; VEGF-D, r¼0.014; Ang-1, r¼0.406; Ang-2,
r¼0.169; and Tie-2, r¼0.516).
Significant difference in the levels of VEGF/PlGF, VEGF-C,
Ang-1, Ang-2, and Tie-2 between healthy controls and AML
patients
The marrow levels of these seven factors in the 52 AML patients at
presentation were compared to those observed in the 20 healthy
controls (Figure 1). Significant differences were observed in
marrow levels of VEGF/PlGF, VEGF-C, Ang-1, Ang-2, and Tie-2
(Po0.005, Po0.0001, Po0.0005, Po0.0001, and Po0.0001,
respectively). The ROC curve illustrated the cut-off value for each
factor from which we could differentiate AML patients from the
healthy controls (Figure 2). Among the seven factors, Ang-2 and
Tie-2 displayed excellent results, with cut-off values of
1039.77pgml
 1 and 11.48ngml
 1, respectively. The AUROC was
0.993 (95% confidence interval (CI), 0.937–0.995; Po0.001) and
0.977 (0.910–0.997; Po0.001), respectively. VEGF-C and Ang-1
displayed good results, with cut-off values of 664.20 and
2556.46pgml
 1, respectively, and the AUROC for these was
0.859 (0.756–0.929, Po0.001) and 0.861 (0.759–0.931, Po0.001),
respectively. The remaining three molecules, ie VEGF-A, VEGF/
PlGF, and VEGF-D displayed poor results, with an AUROC of 0.693
(0.573–0.796, P¼0.009), 0.631 (0.509–0.742, P¼0.063), and 0.667
(0.546–0.774, P¼0.025), respectively.
Sequential analysis of VEGF/PlGF, Ang-2, Tie-2, and VEGF-C
levels in AML patients during the chemotherapy course
Of the 31 AML patients undergoing conventional induction
chemotherapy, 22 (71.0%) patients achieved CR after treatment.
The marrow levels of VEGF/PlGF, Ang-2, Tie-2, and VEGF-C in the
AML patients at presentation were compared to those observed at
the CR stage. VEGF/PlGF and Ang-2 levels increased, while Tie-2
and VEGF-C levels decreased significantly (Po0.005, Po0.005,
P¼0.019, and P¼0.038, respectively). All of these values were
trend to normalise at CR stage as we expected, but they did not fit
into normal range (Figure 3).
Correlation of marrow levels of VEGF/PlGF, VEGF-D, and
Tie-2 with prognosis of AML
Further investigation was performed by using the Kaplan–Meier
survival curve and log-rank test to evaluate the suitability of these
molecules as prognostic factors. Of 31 AML patients undergoing
conventional induction chemotherapy were divided into sub-
groups with high and low levels based on their distributions. The
median follow-up period of the 31 patients was 12.0 months
(range, 0.5–66.1 months). A 5-year survival analysis revealed
significant differences in VEGF/PlGF, VEGF-D, Ang-2, and Tie-2
levels among the subgroups (Figure 4). Groups that demonstrated
marrow VEGF/PlGF levels higher than 1pgml
 1 or VEGF-D levels
higher than 350pgml
 1 demonstrated a greater probability of
survival (P¼0.020, 13.0 vs 26.2 months for VEGF/PlGF and
P¼0.016, 2.5 vs 22.1 months for VEGF-D). However, groups with
marrow Tie-2 levels higher than 26ngml
 1 or Ang-2 levels higher
than 4500pgml
 1 demonstrated a poor prognosis (P¼0.037, 26.2
vs 17.3 months for Tie-2 and P¼0.042, 18.9 vs 7.2 months for
Ang-2). The remaining angiogenesis factors did not reveal any
effect on overall survival. Based on the above results, we devised an
algorithm known as the angio-index that collectively considered
four distinct markers: (Ang-2 in pgml
 1 Tie-2 in ngml
 1)/
(VEGF/PlGF in pgml
 1 VEGF-D in pgml
 1). We discovered that
subgroups with an angio-index greater than 50 had substantially
poor survival probabilities (P¼0.001, 7.2 vs 26.2 months; Figure 4).
In addition, we also analysed the 5-year survival of patients
whether or not they achieved CR after standard chemotherapy, and
discovered that the subgroups that achieved CR had a considerably
better probability of survival (Po0.001, 26.2 vs 2.0 months;
Figure 4). By comparing the probability of CR and the angio-index
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Figure 1 Marrow levels of vascular endothelial growth factor (VEGF)-A,
VEGF/PlGF, VEGF-C, VEGF-D, angiopoietin (Ang)-1, Ang-2, and Tie-2 in 52
AML patients at presentation and in 20 healthy controls. Lower and upper
lines indicate the 25th and 75th percentiles, respectively. The dot in each
bar denotes the median. The P-value was calculated using the Student’s
t-test for the AML patient and control groups.
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sat diagnosis, we found that 18 of 20 (90%) patients with an angio-
index less than 50 achieved CR after standard treatment; this
suggests that the angio-index might be an appropriate indicator for
the prediction of disease outcome.
In addition, by using the univariate Cox regression model, the
angio-index displayed prominent prognosis value, with a hazard
ratio of 4.38 (95% CI, 1.65–11.60, P¼0.003); after adjusting for
age and sex in a multivariate model, the hazard ratio may reach
5.91 (1.99–17.56, P¼0.001).
DISCUSSION
Marrow neoangiogenesis in AML is a complex process involving
the interplay of different angiogenic growth factors. Until now,
most investigators have attempted to elucidate the impact of a
single angiogenic factor on the pathogenesis or prognosis of
haematologic malignancies (Aguayo et al, 2002; Litwin et al, 2002;
Moehler et al, 2003; Liu et al, 2005; Nowicki et al, 2006). However,
HSCs were observed to be in close contact with the marrow
stromal cells in vivo (Oostendorp and Dormer, 1997; Tordjman
et al, 1999). Furthermore, both fibroblasts and microvascular ECs
obtained in normal and leukaemic marrows were reported to
produce several angiogenesis molecules (Moehler et al, 2003; De
Raeve et al, 2004; Ogawa et al, 2006). Therefore, because of the
synchronised action of various angiogenic cytokines, it is
important to elucidate the marrow levels of the various angio-
genesis factors present in the marrow microenvironment. The current
study is the first report on the concentrations of the various
angiogenesis factors in the marrow microenvironment of AML
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Figure 3 Levels of the angiogenesis factors in 22 patients at diagnosis
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(fresh) and first CR stages were compared. The P-value was calculated
using the paired t-test.
Marrow angiogenesis factors in AML
C-Y Lee et al
880
British Journal of Cancer (2007) 97(7), 877–882 & 2007 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
spatients. We found that the marrow levels of VEGF/PlGF, Ang-2,
and Tie-2 were significantly higher (Po0.001) and those of VEGF-
C and Ang-1 were significantly lower (Po0.001) in the AML
patients as compared to those values in healthy controls. In
addition, we found that patients with lower VEGF/PlGF and VEGF-
D levels or higher Ang-2 and Tie-2 levels displayed poor prognosis
(P¼0.020, 0.016, 0.042, and 0.037, respectively). We used the
algorithm angio-index ((Ang-2 Tie-2)/(VEGF/PlGF VEGF-D))
and achieved the most accurate separation of patients with a high-
risk signature from those with a low-risk signature (P¼0.001).
Further, the AML patients with higher angio-index values
displayed poor prognosis, a hazard ratio of 4.38; suggesting that
the combined marrow levels of VEGF/PlGF, VEGF-D, Ang-2, and
Tie-2 facilitated prediction of prognosis. To our knowledge, this is
the first report that evaluated prognosis by devising an algorithm
that combined four distinct angiogenesis-associated factors.
The receptor tyrosine kinase Tie-2 is expressed in the ECs, early
HSCs, and the so-called leukaemic cells (Arai et al, 2004; Arai et al,
2005). Ang-1, but not Ang-2, induces autophosphorylation of the
Tie-2 receptor upon binding (Korpelainen and Alitalo, 1998; Jones,
2003; Thurston, 2003; Peters et al, 2004). Therefore, Ang-1 and
Ang-2 are believed to function as naturally occurring antagonists.
The cellular receptor Tie-2 shedding from the cell surface results in
the release of a soluble receptor from Tie-2-expressing cells
(Reusch et al, 2001). Consequently, the soluble receptor can be
detected in human serum and plasma. Recently, Schliemann et al
(2006) used an immunohistochemical stain to study BM biopsy
samples and discovered that both Ang-2 and Tie-2 were over-
expressed in the leukaemic blasts of AML patients; however, Ang-1
was not Loges et al (2005) employed quantitative RT–PCR to
study mRNA expression and discovered that the median levels of
VEGF-A, VEGF-C, Ang-1, and Ang-2 were higher in PB blasts than
in normal PB AC133
þ cells. In our study, we also found a similar
trend for Ang-2 and Tie-2 in the AML patients; nevertheless, we
further revealed significant differences in the Ang-1, VEGF/PlGF,
and VEGF-C levels between the AML patients and healthy controls.
These reports demonstrated that the Ang-2 and Tie-2 levels
displayed a similar trend in AML patients with regard to cellular
mRNA and proteins and extracellular proteins. However, similar
trends were not observed for VEGF-A, VEGF-C, and Ang-1 levels;
this suggests that the distribution of three angiogenesis-associated
factors in the cells and microenvironment may vary, and while
some display a positive association, others display a negative
association. Therefore, the molecules in intracellular and extra-
cellular environments exhibited different implications in prognosis
prediction. Schliemann et al (2006) discovered that patients
expressing high intracellular Ang-2 levels in leukaemic cells
displayed a significantly extended overall survival than that
displayed by patients with low intracellular Ang-2 levels
Loges et al (2005) discovered that higher Ang-2 mRNA levels
in PB blasts tend to indicate a better prognosis in AML
patients. However, in our study, high marrow levels of extracellular
Ang-2 indicated a poor prognosis. This diversity might be from
different sample origin, one was from PB and the other was
from marrow.
In the angiogenesis process, VEGF-A is usually present in its
homodimeric form. It can also form a heterodimer with PlGF, and
this stimulates angiogenesis via the VEGFR-1/VEGFR-2 hetero-
dimer (Autiero et al, 2003; Roy et al, 2006); this is consistent with
our finding that VEGF/PlGF was present at substantially higher
levels in AML patients than in the healthy controls. Loges et al
(2005) reported that the AML patients and healthy donors
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Figure 4 Kaplan–Meier survival curves for the angiogenesis factors, VEGF/PIGF (A), VEGF-D (B), Ang-2 (C), and Tie-2 (D), as well as angio-index (E)
and complete remission achievement (F). Each angiogenesis factor was divided into high (dot line) and low (solid line) concentration subgroups based on
the distribution of its level. The angio-index was divided into high (dot line) and low (solid line) subgroups with a cut-off value of 50. The P-value was
calculated using the log-rank test. The angio-index stands for the formula (Ang-2 Tie-2)(VEGF/PIGF VEGF-D).
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mRNA expression. Fielder et al (1997) reported that leukaemic
cells expressed VEGF-C in most of the AML patients. Dias et al
(2002) found that VEGF-C that was released from the endothelium
could induce leukaemic cell proliferation, promote their survival,
and protect them from chemotherapy-induced apoptosis. In our
study, we observed a difference in the marrow VEGF-C levels
between the AML patients and healthy controls, but we could not
predict the prognosis of the AML patients based on these levels
(P¼0.591).
Our previous report (Lin et al, 2002) addressed the close
relationship between the marrow matrix metalloproteinase
(MMP)-9 level and the disease status of AML; the marrow MMP-
9 level may be a useful surrogate marker for monitoring the disease
status in AML patients. However, the survival times of AML
patients with lower MMP-9 levels were only slightly longer than
those of AML patients with higher levels (P¼0.12). As observed in
this report, the angio-index involving four angiopoiesis-associated
factors was an appropriate prognostic marker (P¼0.001). There-
fore, the estimation of the marrow MMP-9, VEGF/PlGF, VEGF-D,
Ang-2, and Tie-2 levels may be helpful in predicting the disease
status of AML patients. Further prospective and multi-centre
studies would be worthwhile to verify the wide application of these
biomarkers.
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